SPRY
Ars Pharmaceuticals Inc
NASDAQ · Biotechnology
$10.03
+0.36 (+3.72%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 86.07M | 357.40M | 350.63M | 398.05M |
| Net Income | 7.72M | 35.24M | 44.72M | 41.86M |
| EPS | — | — | — | — |
| Profit Margin | 9.0% | 9.9% | 12.8% | 10.5% |
| Rev Growth | — | +16.3% | -1.3% | +6.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 228.52M | 266.70M | 231.00M |
| Total Equity | — | 545.19M | 556.64M | 584.56M |
| D/E Ratio | — | 0.42 | 0.48 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 8.10M | 65.64M | 71.27M | 76.87M |
| Free Cash Flow | — | 46.75M | 30.69M | 51.61M |